Aegerion Pharmaceuticals Fined $40M for Illegal Marketing of Juxtapid
- Last Updated: August 4th, 2023
Attorney Jessie Paluch, founder of TruLaw, has over 25 years of experience as a personal injury and mass tort attorney, and previously worked as an international tax attorney at Deloitte. Jessie collaborates with attorneys nationwide — enabling her to share reliable, up-to-date legal information with our readers.
Legally Reviewed
This article has been written and reviewed for legal accuracy and clarity by the team of writers and legal experts at TruLaw and is as accurate as possible. This content should not be taken as legal advice from an attorney. If you would like to learn more about our owner and experienced injury lawyer, Jessie Paluch, you can do so here.
Fact-Checked
TruLaw does everything possible to make sure the information in this article is up to date and accurate. If you need specific legal advice about your case, contact us by using the chat on the bottom of this page. This article should not be taken as advice from an attorney.
Aegerion Pharmaceuticals Fined $40M for Illegal Marketing of Juxtapid
On September 22, Aegerion Pharmaceuticals Inc., a subsidiary of Novelion Therapeutics, agreed to plead guilty to two counts of violating the Federal Food, Drug, and Cosmetic (FD&C) Act related to the company’s introduction of misbranded Juxtapid (lomitapide).
Along with the guilty pleas, Aegerion agreed to pay a fine of $40.1 million to the Justice Department and the Security Exchange Commission (SEC), and will enter into a consent decree of permanent injunction with the U.S., which includes participating in a comprehensive FDA compliance program to ensure that the company follows the law.
Table of Contents
Juxtapid Comes With High Price Tag, Serious Side Effects
Yearly treatment with this drug costs $200,000 to $300,000, and along with the hefty price a black box warning of serious side effects related to liver toxicity.
Juxtapid can also increase liver fat, which may lead to a condition known as hepatic steatosis, a risk factor for progressive liver disease.
Due to the risk of liver toxicity, the drug is only available from certified doctors and pharmacies through a special program called the Juxtapid Risk Evaluation and Mitigation Program.
Aegerion Engages in Illegal Marketing
Court documents indicated that the company tried to market the drug indirectly to non-HoFH patients, even though the drug’s approval included a requirement that Aegerion educates doctors about the risks associated with Juxtapid use and that the medication should only be used for patients with a clinical or laboratory diagnosis of HoFH.
There was also evidence that the company was using a definition of HoFH that was not consistent with Aegerion’s pre-approval filings with the FDA and did not match any peer-reviewed clinical standard for diagnosing HoFH.
In addition, Aegerion failed to comply with the requirements of the Juxtapid Risk Evaluation and Mitigation Strategy (REMS) program, according to the FDA.
The U.S. Food and Drug Administration (FDA) approved the drug in December 2012 for the treatment of homozygous familial hypercholesterolemia (HoFH), a rare genetic condition in which patients cannot reduce their LDL or “bad” cholesterol levels with conventional treatment methods.
The condition appears at birth and can cause cardiac disease in patients even before they reach their teenage years.
Juxtapid New Risks
On July 28, the FDA approved labeling changes for Juxtapid to reflect new risks of myalgia and alopecia associated with the medication.
Alopecia has been reported 27 times by Juxtapid patients, and two individuals were hospitalized due to their conditions.
Seventy-three patients reported myalgia with Juxtapid use, with four resulting in hospitalization and two in disability.
Experienced Attorney & Legal SaaS CEO
With over 25 years of legal experience, Jessie is an Illinois lawyer, a CPA, and a mother of three. She spent the first decade of her career working as an international tax attorney at Deloitte.
In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.
In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share reliable legal information with her readers!
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
At TruLaw, we fiercely combat corporations that endanger individuals’ well-being. If you’ve suffered injuries and believe these well-funded entities should be held accountable, we’re here for you.
With TruLaw, you gain access to successful and seasoned lawyers who maximize your chances of success. Our lawyers invest in you—they do not receive a dime until your lawsuit reaches a successful resolution!
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!
AFFF Lawsuit claims are being filed against manufacturers of aqueous film-forming foam (AFFF), commonly used in firefighting.
Claims allege that companies such as 3M, DuPont, and Tyco Fire Products failed to adequately warn users about the potential dangers of AFFF exposure — including increased risks of various cancers and diseases.
Suboxone Tooth Decay Lawsuit claims are being filed against Indivior, the manufacturer of Suboxone, a medication used to treat opioid addiction.
Claims allege that Indivior failed to adequately warn users about the potential dangers of severe tooth decay and dental injuries associated with Suboxone’s sublingual film version.
Social Media Harm Lawsuits are being filed against social media companies for allegedly causing mental health issues in children and teens.
Claims allege that companies like Meta, Google, ByteDance, and Snap designed addictive platforms that led to anxiety, depression, and other mental health issues without adequately warning users or parents.
Transvaginal Mesh Lawsuits are being filed against manufacturers of transvaginal mesh products used to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI).
Claims allege that companies like Ethicon, C.R. Bard, and Boston Scientific failed to adequately warn about potential dangers — including erosion, pain, and infection.
Bair Hugger Warming Blanket Lawsuits involve claims against 3M — alleging their surgical warming blankets caused severe infections and complications (particularly in hip and knee replacement surgeries).
Plaintiffs claim 3M failed to warn about potential risks — despite knowing about increased risk of deep joint infections since 2011.
Baby Formula NEC Lawsuit claims are being filed against manufacturers of cow’s milk-based baby formula products.
Claims allege that companies like Abbott Laboratories (Similac) and Mead Johnson & Company (Enfamil) failed to warn about the increased risk of necrotizing enterocolitis (NEC) in premature infants.
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
